anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
* Bring WinRho ®SDF to room temperature prior to use. 
  * Inspect WinRho ®SDF for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates. 
  * WinRho ®SDF is for single use only. Discard any unused portion. 
  * The solution is ready to use, no reconstitution required.
  * See Table 4for the target fill volumes for each of the dosage sizes for WinRho ®SDF. 



Note:Remove the entire contents of the vial to obtain the labelled dosage of WinRho ®SDF. If partial vials are required for dosage calculation, withdraw the entire contents of the vial to ensure accurate calculation of the dosage requirement. For ease in withdrawing the contents of the vial, draw back the plunger of a sterile syringe (with the needle and needle cover in place) to admit air into the syringe. Depress the plunger of the syringe to inject air into the vial. Invert vial and aspirate contents of vial into syringe.
INTRODUCTION: Immune-mediated necrotizing myopathy (IMNM) is a form of statin myopathy characterized by the presence of antibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti HMGCR).
OBJECTIVES: The aim of this study was to investigate the relationship between the different statins and the risk of IMNM.
METHODS: A two-time approach was used. First, we performed a descriptive analysis of the French national pharmacovigilance database (FNPV) for the period from 1985 to december2020. To identify relevant cases, we used Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) related to IMNM. We performed a quantitative and qualitative review of individual case safety reports (ICSRs) recorded in the french vigilance spontaneous reporting system. In a second time, we performed a comparative analysis with the World Health Organization global individual case safety reports database (Vigibase). The association between IMNM and statins exposure was assessed by calculating the reporting odds ratio (ROR) and its 95% confidence interval.
RESULTS: After analysis, a total of 25 ICSRs were related to IMNM in the FNPV. The suspected statins were atorvastatin (n=21), simvastatin (n=2), pravastatin (n=1) and rosuvastatin (n=1). In Vigibase, 567 notifications were identified. A significant ROR value was found for atorvastatin, pitavastatin, simvastatin, pravastatin and rosuvastatin.
CONCLUSION: Atorvastatin presents the highest risk of IMNM. Our data suggest that the occurrence of IMNM is a class effect.
INTRODUCTION: The traditional sutured venous anastomosis used during arteriovenous graft implantation is associated with a high incidence of subsequent stenosis that is attributed to neointimal hyperplasia. Hyperplasia results from multiple factors, including hemodynamic abnormalities and vessel trauma during implantation. A novel anastomotic connector device was designed to provide an alternative, less traumatic, endovascular venous anastomosis that may ameliorate the clinical challenges associated with a sutured anastomosis. A prospective single-arm multicenter study was performed to evaluate safety and effectiveness of graft implantation using the study device.
METHODS: Patients requiring graft creation and who met the study criteria were enrolled between February 2018 and July 2021 and observed for 6 months. Collected data included baseline characteristics, graft patency and use for hemodialysis, graft interventions, and adverse events. The primary study endpoint was cumulative graft patency, compared to a pre-specified Performance Goal of 75%. Secondary endpoints included primary unassisted patency and serious adverse events, defined as the occurrence of death, graft infection, emergent surgery, significant bleeding, and pseudoaneurysm.
RESULTS: A total of 158 patients were enrolled from 10 study sites, among which 144 subjects were evaluable at 6 months and 14 were censored with partial follow-up observation. Three patients died and the graft was abandoned in 12. The primary endpoint was met (p-value < 0.001). By Kaplan Meier survival analysis, cumulative patency was 92.08% with a lower 95% Confidence Bound of 86.98%. Primary unassisted patency was 60.21% with a lower 95% Confidence Bound of 50.84%. Graft infections occurred in six patients, all unrelated to the study device. There were no reports of emergent surgery, significant bleeding or pseudoaneurysm.
CONCLUSION: These results demonstrate that the study device can be used for successful endovascular anastomosis of a vein to a graft for hemodialysis, with acceptable cumulative patency and safety profile at 6 months.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02532621.
The invention relates to a compound for curing cancer and is characterized in that the compound includes the following ingredients with certain content (weight percentage): mythic fungus germ-entity extract: lucidum spore: Zhiling capsule is 10 to 30 percent: 10 to 30 percent: 40 to 80 percent, with the optimum ratio of 1:1:1.5. The compound can be made into hard capsules, soft capsules, tablets (including ordinary tablets, disintegrating tablets, buccal tablets and chewable tablets), grains and pills, which can be taken by mouth. The preparing method of the compound is characterized in that the mythic fungus germ-entity is firstly extracted with 60 percent ethanol and then with water, with the mythic fungus germ-entity extract obtained after the compounding; the lucidum spore has the shell physically broken up at a low temperature and under the normal pressure, with the shell breaking rate over 95 percent and the grain diameter of 0.4 to 0.5 microns. The lucidum spore which has the shell physically broken up can be firstly extracted with 60 percent ethanol and then with water, with the lucidum spore extract obtained after the compounding. When such extract is used to substitute for the lucidum spore which has the shell broken up, the content (weight percentage) of the ingredients of the compound is that mythic fungus germ-entity: lucidum spore extract: Zhiling capsule is 1 to 3: 0.1 to 0.5: 4 to 8, with the optimum ratio of 1:0.3:1.5. The lucidum spore or the lucidum spore extract can be separately made into hard capsules, soft capsules, tablets (including ordinary tablets, disintegrating tablets, buccal tablets and chewable tablets), grains and pills, which can be taken by mouth. The hard capsules, after mixed with the medical accessorial materials, are firstly made into grains which are then placed into capsules. The compound is easy to be absorbed by the human body and convenient to be used.
The invention discloses an envelope glycoprotein for packaging a transduced NK cell pseudotyped lentiviral vector and application thereof; the envelope glycoprotein comprises an extracellular region, a transmembrane region and a cytoplasmic region; wherein the amino acid sequence or the mutant sequence of the extracellular region is shown as SEQ ID NO. 1 or SEQ ID NO. 2; the amino acid sequence or the mutation sequence of the transmembrane region is shown as SEQ ID NO. 3 or SEQ ID NO. 4; the amino acid sequence or mutant sequence of cytoplasmic region is shown as SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 or SEQ ID NO. 8. The BaEV envelope glycoprotein mutant replaces VSV-G packaging lentivirus pseudovirus, maintains high virus titer of 7.33E+07 TU/mL, can effectively identify NK cells and mediate viruses to enter cells, thereby achieving the purpose of efficiently transfecting the NK cells.
PURPOSE: Axial elongation is the basis of progression in primary myopia and the preferred metric to monitor its evolution. We conducted a meta-regression to model axial elongation and its associated factors in children with low to moderate myopia.
METHODS: A comprehensive electronic systematic search was performed using Ovid Medline, EMBASE, and Cochrane Central Register of Controlled Trials of studies conducted up until October 2021. The mean rate of axial elongation was analyzed using a multivariate linear mixed-effects meta-regression model, with backward stepwise elimination of nonsignificant covariates. The model included three levels of random effects, allowing both prediction and confidence intervals to be estimated.
RESULTS: A total of 64 studies with 83 subpopulations and 142 evaluations of mean axial change from baseline met our inclusion criteria and had no missing significant covariates in the final model. A separate analysis including all populations with axial length data (202 evaluations) but missing variance or covariate data produced a similar model to that for the analysis with complete data. The mean axial elongation is 38% greater in Asian children (95% confidence interval, 19 to 61%; p<0.01) compared with non-Asians, but both groups show a 15% decline per year as age increases (95% confidence interval, 12 to 17% p<0.0001). Prediction intervals indicate substantial variability around the axial elongation estimates.
CONCLUSIONS: This analysis provides mean values of axial elongation for evaluation of efficacy of myopia control. The broad prediction intervals emphasize the large range of individual axial elongation rates in the population, illustrating the challenge in managing individual children. Interpretation of the analysis is limited by the use of aggregated data rather than individual subject data.
This is a multicentre, open-label, single-dose pharmacokinetic trial. A minimum of 24 paediatric subjects (aged ≥ 4 to ≤ 12 years) with functional faecal retention (FFR) were administered a single dose of prucalopride in oral solution.

All subjects who qualified to enter the trial received a single dose of 0.03 mg/kg prucalopride oral solution at Hour 0 on Day 1. One blood sample was drawn prior to dosing, and 13 samples were drawn over the 72-hour interval following the single dose or prucalopride. Urine was collected quantitatively for the first 24 hours. Plasma prepared from blood samples and urine samples were assayed for prucalopride concentrations. Safety was monitored over the 72-hour interval following the dose of trial medication.
Pathological retinal angiogenesis profoundly impacts visual function in vascular eye diseases, such as retinopathy of prematurity (ROP) in preterm infants and age-related macular degeneration in the elderly. While the involvement of photoreceptors in these diseases is recognized, the underlying mechanisms remain unclear. This study delved into the pivotal role of photoreceptors in regulating abnormal retinal blood vessel growth using an oxygen-induced retinopathy (OIR) mouse model through the c-Fos/A disintegrin and metalloprotease 17 (Adam17) axis. Our findings revealed a significant induction of c-Fos expression in rod photoreceptors, and c-Fos depletion in these cells inhibited pathological neovascularization and reduced blood vessel leakage in the OIR mouse model. Mechanistically, c-Fos directly regulated the transcription of Adam17 a shedding protease responsible for the production of bioactive molecules involved in inflammation, angiogenesis, and cell adhesion and migration. Furthermore, we demonstrated the therapeutic potential by using an adeno-associated virus carrying a rod photoreceptor-specific short hairpin RNA against c-fos which effectively mitigated abnormal retinal blood vessel overgrowth, restored retinal thickness, and improved electroretinographic (ERG) responses. In conclusion, this study highlights the significance of photoreceptor c-Fos in ROP pathology, offering a novel perspective for the treatment of this disease.
Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 6 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
Lactose intolerance in humans is due to intestinal lactase deficiency. Lactase is a Sulfur-containing enzyme. A study was undertaken to determine whether lactose tolerance could be restored by Sulfur therapy in patients with lactose intolerance. 17 patients with severe lactose intolerance for an average of 13 years (range 1 to 43 years) were treated with Sublimed Sulfur 200 mg orally twice daily after meals until lactose tolerance was restored.  Sublimed Sulfur was then discontinued. Lactose tolerance was restored after 3 to 5 weeks of treatment with Sublimed Sulfur; the patients subsequently remained symptom-free for diarrhea, abdominal pain and bloating for an average of 26 weeks (range 18 to 62 weeks) on unrestricted intake of milk and milk products. The use of Sublimed Sulfur in the treatment of lactose intolerance resulted in restoration of lactose tolerance in humans.
FIELD: chemistry. ^ SUBSTANCE: invention relates to the technology of processing natural objects. The material used to produce 2,3,6,7-tetrahydroxynaphthazarin (spinochrome E) is wastes from processing sea urchins Strongylocentrotus nudus, which are defrosted or separated from a preserving agent through decantation. The raw material is washed with water, degreased with 96% ethyl alcohol and the extracted three times with 96% ethyl alcohol with addition of phosphoric acid (pH 3.0-3.5) with ratio raw material: extraction agent equal to 1.0:(1.0-1.2) for 12-24 hours.The obtained extract is passed through a column with chitosan. The column is washed with 96% ethyl alcohol and pigments are then eluted with 96% ethyl alcohol with addition of hydrochloric acid (pH 2-4). Further, the eluate is passed through a column with polychrome-1. The column is washed with distilled water and the end product is eluted with 40-50% aqueous solution of ethyl alcohol. The solvent is distilled in a vacuum and the water residue is lyophilised. Spinochrome E is the sublimated at 195-200C or recrystallised from ethyl alcohol. ^ EFFECT: method widens the range of biologically active substances obtained from wastes of industrial processing of sea urchins. ^ 3 dwg, 2 ex
It is well-established that spinal microglia and peripheral macrophages play critical roles in the etiology of neuropathic pain; however, growing evidence suggests sex differences in pain hypersensitivity owing to microglia and macrophages. Therefore, it is crucial to understand sex- and androgen-dependent characteristics of pain-related myeloid cells in mice with nerve injury-induced neuropathic pain. To deplete microglia and macrophages, pexidartinib (PLX3397), an inhibitor of the colony-stimulating factor 1 receptor, was orally administered, and mice were subjected to partial sciatic nerve ligation (PSL). Following PSL induction, healthy male and female mice and male gonadectomized (GDX) mice exhibited similar levels of spinal microglial activation, peripheral macrophage accumulation, and mechanical allodynia. Treatment with PLX3397 significantly suppressed mechanical allodynia in normal males; this was not observed in female and GDX male mice. Sex- and androgen-dependent differences in the PLX3397-mediated preventive effects were observed on spinal microglia and dorsal root ganglia (DRG) macrophages, as well as in expression patterns of pain-related inflammatory mediators in these cells. Conversely, no sex- or androgen-dependent differences were detected in sciatic nerve macrophages, and inhibition of peripheral CC-chemokine receptor 5 prevented neuropathic pain in both sexes. Collectively, these findings demonstrate the presence of considerable sex- and androgen-dependent differences in the etiology of neuropathic pain in spinal microglia and DRG macrophages but not in sciatic nerve macrophages. Given that the mechanisms of neuropathic pain may differ among experimental models and clinical conditions, accumulating several lines of evidence is crucial to comprehensively clarifying the sex-dependent regulatory mechanisms of pain.
This group includes 34 patients who have axillary web syndrome will receive Pilates exercise with traditional physical therapy exercise program (strength, core stability, flexibility, muscle control, posture and breathing). Patients will receive 3 sessions per week for 9 weeks; time of session is 30 minutes.
The invention relates to external medicinal liquor for controlling pig sarcoptidosis, and a preparation method thereof. According to the invention, an auxiliary material of 75% alcohol is adopted as a substrate, such that active components of medicine materials can be fully precipitated. The substrate has high permeability, such that the medicine effect can be directly provided for the disease focus, and pathogenic bacteria can be completely killed. The medicine materials are peach leaves, common monkshood mother-root, kusnezoff monkshood mother-root, sulfur, pomegranata rind, and argy wormwood leaves. The materials are soaked for 10 days, in which shaking is carried out each day, such that the active components of the medicines are fully precipitated. Therefore, the itching relieving, sarcoptes mite killing, detoxifying, tissue regeneration promoting, and pathogenic bacteria killing functions are enhanced. The external medicinal liquor is safe, and has no toxic or side effect. The treatment effect of the external medicinal liquor is substantial and reliable.
BACKGROUND: Many blood banks use upper age limits for donors out of concern for a higher donor complication rate in older donors. Experienced donors are known to have lower donor complication rates, and older donors are often more experienced, confounding the effect of age on donor complication rate.
STUDY DESIGN AND METHODS: We studied donor complication rates in whole blood, plasma, and plateletpheresis donors from 2012 to 2022. Donor complication rates were compared between age groups in inexperienced (<20th donation) and experienced (≥20th donation) donors. In addition to this direct comparison, we made use of logistic regression with finer-grained experience groups, to further quantify the effects of age, experience and other factors on donor complication rate.
RESULTS: While overall rate of vasovagal reaction was lower, rate of moderate/severe vasovagal syncope was highest in 70-79 year donors, however, only reached significance for plasma donors. Furthermore, rates of failed stab were highest in this age group. Hematoma rate showed a U-shaped pattern with regard to age, where the rate was not higher in the 70-79 year age group than in the 18-23 year age group. Pain decreased with age, however, rates were higher in the 70-79 year age group than in the 65-69 year age group.
DISCUSSION: When properly accounting for donor experience, donor complication rate profiles clearly change with age. The increased risk for moderate/severe vasovagal syncope in older donors should be clearly communicated. Extra caution is needed if these donors are accepted for first-time donations.
For the contracting States BE, CH, DE, FR, GB, IT, LI, LU, NL, SE. 1. Compound of formula  see diagramm : EP0043811,P6,F1  in the form of a base or of an organic or mineral acid addition salt, and in the form of the optical isomers or of the racemic mixture. For the contracting state AT. 1. Method for the preparation of the compound of formula see diagramm : EP0043811,P6,F1  in the form of a base or of an organic or mineral acid addition salt, and in the form of the optical isomers or of the racemic mixture, characterized in that the N-ethyl-1,2,3,3a,4,5-hexahydro-canthine-6-one formula  see diagramm : EP0043811,P6,F2  is treated with LiAlH4  in an inert solvant, and the such obtained alcohol is dehydrated by POCl3  in a benzene-triethylamine mixture.
OBJECTIVES: I. Determine the optimal immunological dose of interleukin-12 and rituximab when administered in combination in patients with non-Hodgkin's lymphoma. II. Determine the toxicities associated with this regimen in this patient population. III. Assess the pharmacodynamics of this regimen in these patients. IV. Document observed clinical response to this regimen in these patients.

OUTLINE: This is a dose escalation study of interleukin-12. Patients receive rituximab IV on days 1, 8, 15, and 22. The first cohort of patients receives interleukin-12 SC twice weekly beginning on day 29. Subsequent cohorts receive interleukin-12 SC twice weekly beginning on day 16. Patients with stable or responding disease may continue treatment with interleukin-12 twice weekly for up to 24 weeks or until disease progression. Cohorts of 6-9 patients receive escalating doses of interleukin-12 until the optimal immunological dose is determined. The optimal immunological dose is defined as the dose preceding that at which 2 of 6 or 2 of 9 patients experience dose limiting toxicities or the dose at which there is a maximal increase in gamma interferon, inducible protein-10 (IP-10) and immune cell infiltration into the lymphoma (whichever dose is lower). Following initial dose escalation, 2 additional cohorts of 6 patients receive a fixed dose of interleukin-12 SC twice weekly beginning on day 2. Patients are followed every 3 months for the first year, and then every 6 months for the next 4 years or until disease progression.

PROJECTED ACCRUAL: A maximum of 45 patients will be accrued for this study within 12-13 months.
The trial was amended to extend the length of the trial in order to meet FDA requirements for the post-approval assessment of cardiovascular (CV) safety. The trial now contains 2 time intervals: Period 1 and Period 2. Period 1 refers to the time interval up to this recent protocol amendment and Period 2, the time interval from this protocol amendment until the end of the study. Participants in Period 1 will be re-consented and continue into Period 2. If required, additional participants will be enrolled in Period 2. Stage 1 refers to the prefiling United States Food and Drug Administration (US FDA) requirement to rule out a 80% increased CV risk. Stage 2 refers to the US FDA post-marketing requirement to rule out a 30% increased CV risk. The Stage 1 assessment of CV risk occurred during Period 1 and was based on a meta-analysis of major adverse CV events (MACE) and unstable angina across the omarigliptin Phase 2/Phase 3 program. The Stage 2 assessment will be based on MACE in P018 alone including CV events from both Period 1 and Period 2.
NMES will be implemented simultaneously on quadriceps femoris muscles of both lower limbs using an electrical stimulator (TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile). Four rubber surface electrodes will be placed over motor points. However, since the electrodes will cover big proportion of muscle surface, anatomical distribution of the belly muscle plus visible contraction of it will be considered for correct setting. The stimulation will be delivered by biphasic current, symmetric (compensated) impulses of 45-50 Hz frequency, 400 μsec pulse duration. With a stimulus duration of 25 minutes, and an on-off programming of 5 seconds on (including 0.8 second rise time, 3.4 seconds of plateau and 0.8 second of fall time) and 5 seconds off, at current intensities able to cause maximal visible contractions. The session duration will be 30 minutes and will be applied twice a day.